In a surprising move, the IRS has raised the bar for wind and solar projects to qualify for federal tax credits, requiring significant physical work to begin by July 2025. Discover the implications of these new rules!
Bluesky, the rising social network, is updating its Community Guidelines and inviting user feedback. Discover how these changes aim to enhance user safety and community behavior amidst new regulations!
President Trump's executive order prohibits banks from discriminating against clients based on political or religious beliefs, raising questions about compliance and potential penalties for the banking industry. Can this order reshape how banks operate?
Ethan Guo, aiming to be the youngest to fly solo to all continents, is stuck in Antarctica after his arrest. Accused of illegal landing, he fights to clear his name and continue his cancer research mission.
President Trump is reviewing the federal classification of marijuana, a potential game-changer for its regulation and taxation. Could this lead to legal changes that reflect state laws?
A Legionnaires’ disease outbreak in Central Harlem has surged to 90 cases and 3 fatalities. NYC health officials propose stricter regulations for cooling tower testing to combat the crisis.
Sinclair is exploring a potential merger and considering a spin-off of its ventures unit, which includes the Tennis Channel. With shares rising, could this be a game-changing moment for the media giant?
In a surprising announcement, Trump revealed plans to reclassify marijuana from a Schedule I to a Schedule III drug, which could significantly impact the cannabis market and investor interest. Experts predict that this change could take about a year, but optimism in the industry is rising.
The new White House order allows alternative investments like crypto in 401(k) plans, but experts warn of hidden risks and fees that could jeopardize ordinary investors’ retirement savings.
Dr. Vinay Prasad is back at the FDA's Center for Biologics Evaluation and Research, raising eyebrows after being ousted amid political turmoil and criticism. His return ignites debates about drug approvals and public health leadership under the Trump administration.
